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Abstract Nanoparticles are the new entities that can greatly
limit the various side effects of systemic chemotherapy, and
that coupled with a targeting moiety enables site-specific
delivery of drugs. Folate receptors are overexpressed in
retinoblastoma cells, thus these can specifically uptake the
drug-loaded nanoparticles, thereby increasing the cytotoxicity
at the tumor site. In our work, doxorubicin-loaded chitosan
nanoparticles was prepared and then conjugated to folic acid.
The conjugation efficiency was characterized by nuclear
magnetic resonance and Fourier transform infrared spectros-
copy. Thereafter, the efficacy of FA-conjugated DOX-CNPs
on retinoblastoma cells (Y-79) was analyzed by MTT assay
which demonstrated superior cytotoxic effects as compared to
unconjugated DOX-CNPs and native DOX. This may be due
to enhanced intracellular uptake of DOX-CNPs-FA (30%)
than that of DOX-CNPs (13.24%) and native DOX (5.01%),
resulting from the high affinity of FA for folate receptors.
Finally, the mechanism of doxorubicin-mediated apoptosis in
retinoblastoma cell line (Y-79) was investigated which
demonstrated that the mitochondrial pathway is activated
and that the FA-conjugated DOX-CNPs are most effective
and causes enhanced release of cytochrome c as well as the
activation of downstream caspases to assist in apoptosis.
Thus, the FA-targeted NPs were proved to possess sustain-
able, controlled, and targeted delivery of anticancer drugs
with DOX as a model drug, which may provide a drug
delivery system of precise control and targeting effect for the
treatment of retinoblastoma.
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1 Introduction
Cancer is a debilitating disease that causes millions of death
each year. Though chemotherapeutics do exist to combat
cancer, one of the most serious issues is the nonselective
nature of the chemotherapeutic drugs, which causes
innumerable side effects (Parveen and Sahoo 2008). Thus,
realizing the importance of targeted drug delivery specifi-
cally to the site of action is the need of the hour.
Retinoblastoma is one such cancer that causes serious
malignant intraocular tumor in infants and children and
often results in loss of vision and secondary malignancies
(Abramson 1990; Smith and Donaldson 1991). Recent
treatment options for retinoblastoma include external beam
radiotherapy, episcleral plaque radiotherapy, and cryother-
apy (Amendola et al. 1989), but these are frequently
associated with complications, such as facial deformities,
cataract, radiation retinopathy, and a substantial risk of
secondary tumors (Abramson and Frank 1998). Systemic
chemotherapy is also limited by toxicity, rapid blood
clearance, and multi-drug resistance (Chan et al. 1989).
Moreover, ocular drug delivery is also impaired due to the
natural defensive barriers of the retina that protect the eye.
Thus, targeting it in a safe and effecting manner would be
helpful to the majority of children diagnosed with retino-
blastoma, especially in developing countries where the
probability of survival is closer to 50% due to poor
education, lower socioeconomic status and inadequate
healthcare systems, which results in delayed diagnosis and
suboptimal care (Rodriguez-Galindo et al. 2008).
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Nanoparticles (NPs) are promising entities that can
greatly reduce the problems due to drug delivery and
retention. These are submicron-sized polymeric colloidal
particles, with diameters ranging from 10 to 1,000 nm, in
which the therapeutic agent of interest can be encapsu-
lated within the polymeric matrix or adsorbed or
conjugated onto the surface (Parveen and Sahoo 2008;
Sahoo and Labhasetwar 2003; Sahoo et al. 2007).
Chitosan nanoparticles (CNPs) are especially suitable for
ocular drug delivery due to their mucoadhesiveness and
ability to cross the tight epithelial junctions, thus increas-
ing the residence time of the drug (Calvo et al. 1997b; de
Campos et al. 2001; Genta et al. 1997). Moreover, these
NPs can be surface functionalized by specific ligands to
achieve targeted drug delivery to the tumor site, thus
improving the therapeutic efficacy and reducing the side
effects of chemotherapy. Several studies have shown that
folic acid (FA) is an attractive targeting moiety for cancer
therapy due to its high affinity for folate receptors (Kd∼
10−10 M; Leamon and Reddy 2004; Lu and Low 2003; Lu
et al. 2004). Folate receptors are overexpressed in the
membrane of many human cancer cells such as brain,
kidney, breast, lung, retinoblastoma, etc. (Kansara et al.
2008; Saul et al. 2003; Sudimack and Lee 2000) and the
expression level of folate receptor in tumors is around
100–300 times higher than in normal tissues (Ross et al.
1994). Thus, because of this distinguishing property, FA
has emerged as an appropriate targeting ligand and can be
exploited in designing a suitable convey system that can
specifically deliver the drug pay load at the therapeutic
site.
In this study, we evaluated the therapeutic effects of folate-
decorated chitosan nanoparticles (CNPs-FA) for targeted
delivery of hydrophilic anticancer drugs with doxorubicin
(DOX), chosen as the model drug, as it is widely used
chemotherapeutic drug for the treatment of retinoblastoma
(Serpe et al. 2006). The drug-loaded CNPs (DOX-CNPs)
were prepared and decorated with folic acid (DOX-CNPs-
FA), which was then characterized by various analytical
techniques such as laser light scattering for particle’s size,
zeta potential analyzer for surface charge, and nuclear
magnetic resonance (NMR) and Fourier transform infrared
spectroscopy (FTIR) for surface chemistry. Thereafter,
comparative analysis of intracellular uptake of drug and
drug-loaded CNPs (conjugated and unconjugated nanopar-
ticles) on retinoblastoma cells (Y-79) was carried out to
access the specificity of the folate receptors and to ascertain
whether nanoparticles are taken up more than the native
drug. The therapeutic effect of doxorubicin formulated in the
CNPs (with folate targeting effect) was also evaluated in
vitro by measuring the viability and the extent of apoptosis of
human retinoblastoma cells (Y-79). Furthermore, the DOX-
mediated apoptotic pathway was investigated wherein the
effects of various formulations on the kinetics of cytochrome
c release, mitochondrial membrane potential, and activation
of various downstream caspases were analyzed by western
blotting.
2 Materials and methods
2.1 Materials
Chitosan (60–90 kDa, degree of deacetylation=85%,
derived from crab shells, in the form of fibrillar flakes),
sodium triphosphate pentabasic (TPP), doxorubicin, folic
acid, sodium chloride, disodium hydrogen phosphate, and
potassium chloride were obtained from Sigma-Aldrich Co.
(St Louis, MO, USA). Propidium iodide (PI) was obtained
from Invitrogen (Leiden, The Netherlands). Potassium
hydrogen phosphate and dimethyl sulfoxide were pur-
chased from Qualigens Fine Chemicals, Mumbai. Acetoni-
trile was purchased from E-merk, India. Ultrapure water
(Millipore, Bedford, MA, USA) was used throughout. All
other chemicals were of analytical grade unless where
otherwise stated.
2.2 Preparation of doxorubicin-loaded chitosan
nanoparticles
Doxorubicin-loaded CNPs were prepared by a modified
ionic gelation method as reported by Calvo et al. (1997a,
b). Briefly, 2 ml of an aqueous solution of TPP (2.91 mg/
ml) was slowly added drop wise into 10 ml of chitosan
solution (1.75 mg/ml, pH=5) containing DOX (5.25 mg).
After overnight stirring, the CNPs were collected by
centrifugation (SIGMA 3K30, Germany) at 18,000 rpm
for 30 min at 4°C. The pellets were then dispersed in
double distilled water and lyophilized (LYPHLOCK,
Labconco, MO) for 48 h and then stored at 4°C for further
studies.
2.3 Nanoparticle surface modification: synthesis of folate
CNPs
Folate-conjugated CNPs were synthesized by coupling the
freeze-dried CNPs to an activated folic acid as described in
previous studies with minor modifications (Guo et al. 2000;
Lee and Low 1995). Briefly, 5 mg of the freeze-dried CNPs
dissolved in 5 ml of DMSO were mixed with 1.3 mg of
folic acid and 1.3 mg of DCC. The reaction was performed
at room temperature for 7 h and then mixed with 50 ml of
distilled water and centrifuged at 3,000 rpm. The pellet was
then dialyzed and dried to obtain CNPs-FA. The formation
of folate-conjugated CNPs was monitored and confirmed
by analyzing the concentration of conjugated folic acid in a
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known amount of the sample at 365 nm by a UV–Visible
spectrophotometer (Synergy HT, BioTek® Instruments Inc.,
Winooski, VT; Yoo and Park 2004). Serially diluted
concentrations of folic acid in DMSO were used to
construct a calibration curve.
2.4 Characterization of doxorubicin-loaded CNPs
with folate decoration
2.4.1 Particle size analysis and zeta potential measurement
Mean particle size and size distribution of the nanoparticles
was determined by photon correlation spectroscopy (PCS)
and laser Doppler anemometry, respectively, using a
Zetasizer (Nano ZS, Malvern Instruments, UK), with a
red laser of wavelength 1o=633 nm (He-Ne, 4.0 Mw). PCS
makes it possible to calculate the average diffusion
coefficient (D) of the particles. Assuming that the particles
are solid, the mean diameter (d) can be easily calculated by
the Stokes–Einstein (Finsy 1994).
d ¼ Kt
3lhD
Where k is the Boltzman constant, T is the absolute
temperature, and η is the viscosity of the medium. For size
measurements, ∼1 mg of CNPs was dissolved in 1 ml of
water which was further diluted with water and measured
for a minimum of 120 s. Zeta potential measurements were
made similarly with ∼1 mg of CNPs dissolved in 1 ml of
water which was further diluted and placed in an
electrophoretic cell, where a potential of ±150 mV was
established. All the samples were maintained at a constant
temperature of 25.0±0.1°C in all experiments, and each
batch was analyzed in triplicates.
2.4.2 Transmission electron microscopic studies
Particle morphology was examined by transmission electron
microscopy (TEM, Philips CM-10, FEI Inc., Hillsboro, OR,
USA). Samples (nanoparticulate suspensions, 100 μg/ml) were
dropped into Formvar-coated copper grids, and after complete
drying, the samples were stained using 2% w/v uranyl acetate
(Electron Microscopy Services, Ft. Washington, PA). Image
capture and analysis were done using Digital Micrograph and
Soft Imaging Viewer Software.
2.4.3 Surface morphology
Scanning electron microscopy The surface morphology of
CNPs was studied by scanning electron microscopy (SEM).
For this, CNPs were sputtered with gold to make them
conductive and placed on a copper stub. The images were
taken using scanning electron microscope (JSM-T220A,
JEOL, MA).
Atomic force microscopy The surface properties of the
formulated CNPs were observed by an atomic force
microscopy (NanoScope III A, Veeco, USA). Explorer
atomic force microscope was a tapping mode, using high
resonance frequency (Fo=312 kHz), pyramidal cantilevers
with silicon probes having force constants of 20 N/m. Scan
speed was set at 2 Hz. The samples were dissolved in PBS
(0.1 M, pH 7.4) and then dropped on freshly cleaved mica
plates, followed by vacuum drying for 24 h at 25°C.
2.4.4 Surface chemistry
Nuclear magnetic resonance The decoration of FA on the
surface of doxorubicin-loaded CNPs was confirmed by
NMR. The NMR spectra was recorded on a spectrometer
(FT NMR Spectrometer, JEOL, 400 MHz, Japan) at
room temperature using DMSO as a solvent (Wan et al.
2008).
Fourier transform infrared spectroscopy The FTIR trans-
mission spectrum of various samples (folic acid, DOX, and
DOX-CNPs-FA) was obtained from SPECTRUM RX I
(Perkin Elmer, FTIR Spectrometer, USA). A total of 2% (w/
w) of sample, with respect to potassium bromide (KBr),
was mixed with dry KBr, and the mixture was ground into
fine powder using an agate mortar before compressing into
KBr disc under a hydraulic press at 10,000 psi. Each KBr
disc was then scanned at 4 mm/s at a resolution of 2 cm−1
over a wave number region of 400–4,000 cm−1 using IR
solution software (ver.1.10), and the characteristic peaks for
different samples were recorded.
2.4.5 Drug encapsulation efficiency
The encapsulation efficiency (EE%) was determined by the
separation of nanoparticles from the aqueous medium
containing non-associated doxorubicin by centrifugation
of the samples at 18,000 rpm for 30 min at 4°C (SIGMA 1–
15K, Germany). The supernatant was used to estimate the
drug concentration which was not encapsulated in the NPs
by fluorescence spectrophotometer (Synergy HT, BioTek®
Instruments Inc., Winooski, VT) at 1ex=485 nm and 1em=
591 nm (Misra and Sahoo 2010). Doxorubicin solutions of
various concentrations were prepared and similarly quanti-
fied to generate a calibration curve for the EE calculations
for the doxorubicin-loaded CNPs. Triplicate samples
(supernatants) were analyzed, and the doxorubicin encap-
sulation efficiency was calculated by dividing the amount
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of doxorubicin entrapped by the total amount of doxorubi-
cin added, multiplied by 100.
2.5 In vitro release kinetics
Freeze-dried CNPs (∼5 mg) were resuspended in 1 ml of
phosphate-buffered saline solution (PBS, pH 7.4) and
incubated at 37°C under light agitation of 150 rpm using
an incubator shaker (Wadegati Labequip, India; n=3). At
appropriate time intervals, individual samples were collect-
ed by centrifugation (SIGMA 3K30, Germany) at
18,000 rpm for 10 min, and the amount of the drug in the
release medium was determined by fluorescence spectro-
photometer (Synergy HT, BioTek® Instruments Inc.,
Winooski, VT) at 1ex=485 nm and 1em=591 nm (Misra
and Sahoo 2010). Calibration curves were made with the
incubation medium, and all measurements were performed
in triplicates.
2.6 Cell culture
Human retinoblastoma cell line (Y-79) was obtained from
the American Type Culture Collection (ATCC, Manassas,
VA) and were cultured in RPMI 1640 with 10% fetal
bovine serum and 1% penicillin–streptomycin at 37°C in a
humidified 95% air/5% CO2 incubator (Hera Cell, Thermo
Scientific, Waltham, MA). All reagents for cell culture were
obtained from Himedia Laboratories Pvt. Ltd., Mumbai,
India.
2.7 Assessment of cytotoxicity
The antiproliferative activity of doxorubicin was analyzed
by the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazoli-
um bromide (MTT)-based colorimetric assay (Mosmann
1983). The MTT assay is a quantitative and rapid
colorimetric method, based on the cleavage of a yellow
tetrazolium salt to insoluble purple formazan crystals by the
mitochondrial dehydrogenase of viable cells (Al-Joudi et al.
2005). The MTT assay was carried out according to a
previously reported procedure (Sahoo and Labhasetwar
2005). Y-79 cells were seeded at 5,000 per well density in
96 well plates (Corning, NY, USA), and after 24 h, drug
either as a solution or encapsulated in nanoparticles at
different concentrations (0.1–100 μM/ml) was added to
separate wells. Medium and void nanoparticles (without
drug) served as respective controls. Medium was changed
on day 2 after the treatment and then every alternate day,
and no further dose of the drug was added. After the
specified incubation time (5 days), 10 μl MTT (Sigma) was
added, and the plates were incubated for 3 h at 37°C in a
cell culture incubator (Hera Cell, Thermo Scientific,
Waltham, MA), following which the intracellular formazan
crystals were solubilized in dimethyl sulfoxide and the
color intensity measured at 540 nm using a microplate
reader (Synergy HT, BioTek Instruments, Inc., Winooski,
VT). The antiproliferative effect of different treatments was
calculated as a percentage of cell growth with respect to
respective controls.
2.8 Assessment of apoptosis by flow cytometry
Annexin V-FITC staining was used for the assessment of
apoptosis. This assay is based on the observation that soon
after the initiation of apoptosis, phosphotidylserine (PS)
translocates from the inner face of the plasma membrane to
the cell surface. The translocated PS can thus be easily
detected by staining with a FITC conjugate of Annexin V, a
protein that has a strong natural affinity for PS (Koopman et
al. 1994). The induction of apoptosis by DOX, DOX-CNPs,
and DOX-CNPs-FA was studied by flow cytometry. In
25 cm2 culture flasks (Corning, NY, USA), 1×105 cells/ml
were grown overnight, after which 5 μM/ml concentration of
free DOX and equivalent concentration of various formula-
tions of DOX-loaded CNPs were added to the flasks, and the
cells were incubated for 48 h in CO2 incubator (Hera Cell,
Thermo Scientific, Waltham, MA). After the specified
incubation periods, the cells were washed thrice with PBS
(0.1 M, pH 7.4) and then resuspended in 100 μl of 1×
binding buffer (Clontech Laboratories, Inc., Palo Alto, CA).
Thereafter, 5 μl Annexin V-FITC (final concentration, 1 μg/
ml; BD Biosciences Pharmingen) and 5 μl propidium iodide
(10 μg/μl; MP Biomedicals, Inc., Germany) were added to
the cells and incubated at room temperature in dark for
20 min. Before flow cytometric analysis, 400 μl of 1×
binding buffer were added to the cells and the extent of
apoptosis was determined by analyzing 15,000 ungated cells
using a FACScan flow cytometer and Cell Quest software
(FACSCalibur; Becton-Dickinson, San Jose, CA).
2.9 Cell cycle distribution analysis by flow cytometry
The effects of CNPs on cell cycle progression and
population distribution were determined by flow cytometry.
Y-79 cells were seeded at 1×105 cells/ml in 75-cm2 flask
(Corning, NY, USA), and it was treated with 5 μM/ml of
DOX, DOX-CNPs, and DOX-CNPs-FA. Doxorubicin-
induced cell cycle arrest was detected by comparing the
cell cycle profiles between doxorubicin-treated cells and
CNP-treated cells with that of the control cells. Forty-eight
hours posttreatment, the cells were collected by centrifuga-
tion, washed thrice with PBS (0.1 M, pH 7.4) to remove
any uninternalized CNPs or the native doxorubicin, and
thereafter, cells were incubated in propidium iodide (20 μg/
ml) for 30 min. The DNA content was measured for 15,000
events for each sample (FACS Caliber instrument; Becton,
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Dickinson & Co, Franklin Lakes, NJ). Data were plotted
using CellQuest software (Becton, Dickinson & Co).
2.10 Assessment of cellular uptake
Twenty-four well plates (Corning, NY, USA) were seeded
with Y-79 cells at 5×104 cells per well density and 24 h
post-seeding, the medium in each well was replaced with
1 ml of freshly prepared suspension of DOX-CNPs and
DOX-CNPs-FA in medium (300 μg/well), and the plates
were incubated for 2 h as described earlier in our previous
paper (Parveen et al. 2010). An equivalent concentration of
doxorubicin was also added to the cells.
For folic acid competition experiments, the cells were
cultured overnight with 0–3 mM folic acid prior to the
addition of the particles. The experiment was terminated
after 2 h by washing the cell monolayer thrice with ice-cold
PBS, 0.1 M, pH 7.4, and lysing the cells by incubating with
0.1 ml of 1× cell lysis buffer (Promega, Madison, WI) for
30 min at 37°C. The cells were washed thrice and
resuspended in PBS (0.1 M, pH 7.4). The amount of
endocytosed particles inside cells was analyzed by FacsCa-
libur flow cytometry. The mean fluorescence intensity
(MFI) of the cells at FITC-A was measured.
2.11 Confocal laser scanning microscopic studies
To study the intracellular retention of the drug, Y-79 cells
were seeded in Bioptechs plates (Bioptechs, Butler, PA) at
5×104 cells per plate in 1 ml of growth medium 24 h prior
to the experiment. Thereafter, cells were treated with 5 μM/
ml of either the native drug, DOX in solution, or DOX-
loaded CNPs (DOX-CNPs and DOX-CNPs-FA). Untreated
cells were used as control to account for the autofluor-
escence, if any. The medium was changed on day 2 after
the treatment and then every alternate day, and no further
dose of DOX was added. At different time points, the cells
were washed thrice with PBS (0.1 M, pH 7.4) to remove
any uninternalized drug/CNPs and then visualized using a
confocal microscope (Leica TCS SP5, Leica Microsystems
GmbH, Germany) that is equipped with an argon laser with
an excitation wavelength set at 488 nm and emission at
590 nm (Janes et al. 2001). Detection was with a band-pass
emission barrier filter. The images were processed using
Leica Application Suite software.
2.12 Mitochondrial transmembrane potential
The mitochondrial membrane potential changes were
analyzed by flow cytometry using a mitochondria-
selective dye JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetrae-
thylbenzimidazolcarbocyanine; Sigma-Aldrich Chemicals,
Germany) (Rees et al. 1991; White and Reynolds 1996).
JC-1 is a lipophilic cation, which in normal polarized
mitochondria exists as aggregates. Depolarization due to
loss of mitochondrial membrane potential causes the
aggregates to dissolute into the monomeric forms. Thus,
JC-1 forms either J-aggregates or monomers, depending
on the state of the mitochondrial membrane potential, with
the missions of the two dye forms detectable by flow
cytometry at 585 (FL2) or 530 nm (FL1), respectively
(Cossarizza et al. 1993). For the JC-1 analysis, cells (2×
105) were treated with 5 μM/ml of native DOX, DOX-
CNPs, and DOX-CNPs-FA for 48 h at 37°C. Thereafter,
the cells were collected by centrifugation, washed thrice
with PBS (0.1 M, pH 7.4) to remove any uninternalized
CNPs or the native doxorubicin, and thereafter, cells were
stained with JC-1 for 15 min at 37°C, washed thrice with
PBS (0.1 M, pH 7.4), and analyzed for changes in
membrane potential by FACScan flow cytometer and Cell
Quest software (FACSCalibur; Becton-Dickinson, San
Jose, CA). All experiments were performed in triplicates.
2.13 Determination of cytochrome c release by western blot
analysis
Cytosolic and mitochondrial fractions were analyzed for
cytochrome c content by immunoblotting. Briefly, Y-79
cells (1×106) were treated with 5 μM/ml of native DOX,
DOX-CNPs, and DOX-CNPs-FA for different time inter-
vals (2, 24, and 48 h) at 37°C. Thereafter, cells were
harvested and washed thrice with cold PBS (0.1 M, pH 7.4)
and sedimented by centrifugation. Cell fractionization was
performed as described by the group of Bialik et al. (1999).
The cell pellet was resuspended in digitonin lysis buffer
(75 mM NaCl, 1 mM NaH2PO4, 8 mM Na2HPO4, 250 mM
sucrose, 190 μg/ml digitonin; 150 μl/100-mm dish) and
incubated on ice for 5 min. The cells were centrifuged
(SIGMA 3K30, Germany) for 5 min at 14,000 rpm at 4°C,
and 1.5 μl of protease inhibitor (Protease Inhibitor Mixture
Set I, Calbiochem) was added. The pellet was then
resuspended in 80 μl of radioimmune precipitation buffer
(1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1%
SDS in phosphate-buffered saline) with protease inhibitor
(1:100 dilution). Radioimmune precipitation buffer is more
denaturing than NP-40 or Triton X-100 lysis buffer because
it contains the ionic detergents SDS and sodium deoxy-
cholate as active constituents. It is particularly useful for
membrane disruption. The pellet was then incubated on ice
for 30 min, and then centrifuged (SIGMA 3K30, Germany)
for 15 min at 14,000 rpm at 4°C. The supernatant was
saved as the cytosolic fraction, whereas the pellet consti-
tuted the mitochondrial fraction.
The soluble protein concentration was determined by
the Pierce BCA protein assay (Pierce, Rockford, IL).
Protein immunodetection was done by electrophoretic
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transfer of SDS-PAGE separated proteins to PDVF
membrane, incubation with primary antibody (antibodies
used were against cytochrome c (Mouse monoclonal
antibody, catalog no. IMG-101A, Imgenex Corporation,
San Diego, USA)) and β-actin (Mouse monoclonal
antibody, catalog no. sc-47778, Santa Cruz Biotechnology,
Santa Cruz, CA) in 1:1,000 dilutions for 1 h at room
temperature and secondary antibody (1:5,000 dilution) for
40 min at room temperature and chemiluminescent second
step detection (Santa Cruz Biotechnology, Santa Cruz,
CA). Anti-mouse secondary antibodies (catalog no.
20,101) were obtained from Imgenex Corporation, San
Diego, USA and used as per recommended antibody
dilution of 1:5,000.
2.14 Determination of caspase activation
Y-79 cells (1×106) were seeded in 25 cm2 culture flasks
(Corning, NY, USA) and treated with 5 μM/ml of native
DOX, DOX-CNPs, and DOX-CNPs-FA for 48 h at 37°C.
Thereafter, the cells were collected, washed thrice with PBS
(0.1 M, pH 7.4), and then pelleted by centrifugation
(SIGMA 3K30, Germany) at 1,000 rpm. The pellet was
resuspended in radioimmune precipitation buffer, incubated
on ice for 30 min, and spun for 15 min at 14,000 rpm at 4°
C to remove the insoluble material. Subsequently, the
activities of caspase-9 and caspase-3 were determined by
western blot analysis as described above. Antibodies used
were against caspase-9 (rabbit polyclonal antibody, catalog
no. 9502) and caspase-3 (rabbit polyclonal antibody,
catalog no. 9662) in 1:1,000 dilutions from Cell Signaling
Technology, Inc., MA. Anti-rabbit secondary antibodies
(catalog no. 20301) were obtained from Imgenex Corpora-
tion, San Diego, USA and used as per the recommended
antibody dilution of 1:5,000. Both primary and secondary
β-actin was used in the dilutions mentioned previously.
2.15 Statistical analysis
All experiments were repeated at least three times. Statistical
analyses were performed using a Student’s t test. The
differences were considered significant for p values of <0.05.
3 Results
This study shows that nanoparticulate forms of the
anticancer drug doxorubicin can be specifically targeted to
cancer cells in a ligand-targeted manner.
3.1 Nanoparticles characterization
Chitosan was used to formulate nanoparticles containing the
chemotherapeutic drug doxorubicin using a modified ion
gelation method. The doxorubicin loading in nanoparticles is
30% w/w with entrapment efficiency of ∼35%, suggesting
that most of the doxorubicin added in the formulation is
entrapped inside the nanoparticles. The drug EE of the NPs
is crucial to justify their clinical applications. The particle
size of these nanoparticles is ∼300 nm as determined by the
particle size analyzer. This was further confirmed by TEM in
which the NPs are seen to be distinct, spherical particles with
solid dense structure, with a size of ∼200 nm (Fig. 1a). The
nanoparticles appear to be considerably smaller as compared
to the average particle size observed with the particle size
analyzer, presumably arising from the dry state of the TEM
measurements. The nanoparticles were further characterized
by SEM. The particles were spherical with a smooth exterior
as evident from SEM results (Fig. 1b). Furthermore, the
surface morphology of the NPs was also analyzed by AFM
which corroborated the results of SEM and confirmed that
the NPs had a smooth and spherical appearance (Fig. 1c).
The average zeta potential of the NPs was ∼30 mV which
200 nm
50 nm 
(a) (b) (c) 
Fig. 1 Physicochemical characterization of CNP-FA. a Transmission electron micrograph. b Scanning electron microscopic images. c AFM
images of CNPs-FA
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shows that the NPs are positively charged. Folate-conjugated
CNPs also did not show a significant variation in the size
and zeta potential values.
The conjugation of folic acid to the surface of NPs was
confirmed by NMR (Fig. 2). It is apparent that the spectrum
of the conjugate contains signals originating from folic acid
and chitosan. The signals at 3.5–4.0 ppm are due to
hydrogen bonded to the carbon atoms 3, 4, 5, and 6 of
the glycopyranose unit and that at 1.9–2.0 ppm correspond
to the hydrogen atoms of the methyl moieties of the
acetamido groups of chitosan (Ji et al., 2009). Moreover,
the signals at 6.7 and 7.6 ppm correspond to the para-
aminobenzoic acid (PABA) from the folate, and the signal
at 8.7 ppm corresponds to the pteridine moiety proton from
the folate (Kim et al. 2007). The chemical modification of
NPs by folic acid also resulted in the appearance of a
characteristic peak at 7.4 ppm (Wan et al. 2008). The
conjugation efficiency of folic acid to CNPs as determined
by UV–Visible spectrophotometer revealed that ∼0.33 mg
of FA was conjugated per milligram of CNPs. The
schematic representation of folic acid conjugated to
chitosan is depicted in Fig. 2c.
The IR spectra of folic acid, doxorubicin, and DOX-







Fig. 2 1H NMR spectra of a
chitosan, b CNP-FA conjugate,
and c schematic representation of
folic acid conjugated to chitosan
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successful conjugation between CNPs and FA as is evident
by the presence of the characteristic peaks of folic acid
at ∼1,638 cm−1 (–CONH amide band II) and ∼1,546 cm−1
(–NH amide band II) in DOX-CNPs-FA. Furthermore, the
absorption of amide band II at 1,638 cm−1 increased, which
may be due to the formation of the amide linkage between
the amino group on the CNPs and the carboxyl group of FA
(Sahu et al. 2010). FTIR is also one of the best techniques
to know the chemical stability of the encapsulated drug
inside the NPs as is evident from studies done by our group
and others (Misra and Sahoo 2010; Mundargi et al. 2007).
Thus, FTIR was also done to assess the chemical stability
of DOX in our nanoparticulate formulations. Native DOX
showed characteristic bands due to presence of different
functional groups. A band appearing at ∼3,331 cm−1 is due
to O-H/N-H stretching vibrations, while those observed
at ∼2,932 cm−1 is due to the C-H stretching vibration.
Bands at ∼1,582 and ∼1,413 cm−1 are due to aromatic N-H
bending vibrations and C-H bending vibrations, respective-
ly. The bands at ∼1,285 and ∼1,212 cm−1 belong to C-N
stretching vibrations. These distinctive bands of native
DOX were also present in DOX-loaded NPs which
indicated the chemical stability of DOX in the nano-
particulate formulation (Misra and Sahoo 2010). The
average cumulative percent release profile of DOX from
the NPs at prefixed time intervals is represented in Fig. 3b.
It was apparent that DOX release in vitro showed a very
rapid initial burst, and then followed by a slow release.
DOX-CNPs showed biphasic release kinetics: initially a
















































Fig. 3 a Nanoparticle characterization by FTIR. Figure depicts FTIR spectra of (i) folic acid, (ii) doxorubicin, and (iii) DOX-CNPs-FA. b In vitro
DOX release profiles from CNPs. Data represent mean±S.D., n=3
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released in 12 h and thereafter sustained release for days
(∼50% of DOX was released in 7 days).
3.2 Effects of DOX on in vitro cytotoxicity, apoptosis,
and Y-79 cell cycle progression and proliferation
To examine the antitumor activity of doxorubicin in human
retinoblastoma Y-79 cells, exponentially dividing cells were
treated with increasing concentrations of native DOX, DOX-
CNPs, and DOX-CNPs-FA, and the cell viability was
measured. The in vitro viability of Y-79 cells after treatment
with various concentrations of the different formulations is
shown in Fig. 4. Though, DOX caused marked growth
inhibition and significantly decreased cell viability, it was
evident that the NP formulation, at all concentrations,
demonstrated significant cytotoxicity versus the native drug.
Moreover, the figure clearly demonstrates the targeting effect
of the folate decoration on DOX-CNPs as the IC50 value
decreased to 3.06 μM as compared to DOX-CNPs
(10.2 μM) and native DOX (15.11 μM). As apoptosis is
considered the key mechanism linked with chemotherapy-
induced cell death, the extent of apoptosis was analyzed by
Annexin V analysis of externalized phosphatidylserine. As
evident from Fig. 5, all the CNP formulations showed
greater apoptotic effect than native DOX. The extent of
apoptosis was 60.2% for DOX-CNPs-FA, 38.04% for DOX-
CNPs, and 16.43% for native DOX clearly indicating the
efficacy of DOX-CNP-FA over other formulations. Although
it was apparent that DOX was cytotoxic to Y-79 cells, the
sustained growth-inhibitory effects observed by the cell
viability assay indicate that DOX might also affect cell
proliferation. To assess whether DOX induced growth
inhibition, we evaluated the effect of native DOX, DOX-
CNPs, and DOX-CNPs-FA on cell cycle progression in Y-79
cells by flow cytometry. As evident from the enhanced
G2/M phase inhibition, folate-decorated DOX-CNPs do
significantly exert a greater antiproliferative effect than
DOX-CNPs as well as native DOX (Fig. 6). Thus, the
results demonstrate that DOX inhibits tumor cell growth by
exerting greater cytotoxic effects on Y-79 cells.
3.3 Cellular uptake as a function of particle surface
modification
As Y-79 cells have a high level of the folic acid receptor on
their surface (Kansara et al. 2008), the targeting effect of
folate-decorated NPs can be evaluated by investigating the
cellular uptake of the NPs. The uptakes of native DOX,
DOX-CNPs, and DOX-CNPs-FA by Y-79 cancer cells were
studied by flow cytometry under in vitro conditions. As
shown in Fig. 7a, b, flow cytometry measurements indicate
that about 31.23% of the cells showed enhanced fluores-
cence when incubated with folate-decorated NPs, which was
around sixfold greater than the native DOX (5.01%). DOX-



























Fig. 4 Evaluation of in vitro cytotoxicity by the MTT assay. Different
concentrations of doxorubicin were added either as solution or
encapsulated in nanoparticles (DOX-CNPs, DOX-CNP-FA) to the wells
with medium as control in Y-79 cell line. Medium was changed at 2 days
and then every alternate day thereafter with no further dose of the drug
added. The extent of growth inhibition was measured at 5 days by the
MTT assay. Data as mean±S.E.M., n=6. **p<0.005, DOX in solution
versus DOX-CNPs and DOX-CNP-FA. *p<0.05, DOX in solution
versus DOX-CNPs and DOX-CNP-FA (black square—native DOX,
black circle—DOX-CNPs, black triangle—DOX-CNP-FA). Void CNPs
had no significant toxicity in the Y-79 cell line
Control DOX
DOX-CNPs DOX-CNPs-FA 
Fig. 5 Induction of apoptosis in Y-79 cell line by native DOX, DOX-
CNPs, and DOX-CNP-FA. Cells were treated with 5 μM of native
DOX and equivalent concentrations of DOX in NPs (DOX-CNP and
DOX-CNP-FA) for 48 h and were then stained with Annexin V to
access the apoptotic potential by flow cytometry. Results are
representative of one of three independent experiments
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(13.24%) than the native drug. To verify that the uptake is
mediated via the folate receptor, a competitive experiment
using different amounts of native folic acid in cell culture
medium together with folate-decorated NPs was performed.
As shown in Fig. 7c, the number of Y-79 cells that had
internalized the FA-functionalized NPs decreased with
increasing concentrations of free FA. At the highest free
folic acid concentration evaluated (3 mM), the MFI value
decreased around fivefold as compared to the value
measured in the absence of free FA.
Targeting effect of DOX-CNPs-FAwas also investigated by
using confocal laser scanning microscopy to further confirm
the enhanced intracellular uptake of the folate-decorated NPs.
Y-79 cells, incubated with free DOX in solution, demonstrated
drug internalization within 2 h of incubation, but with increase
in incubation time, the fluorescent intensity was reduced
slowly. DOX-CNPs-FA-loaded nanoparticles on the other
hand, were more strongly stained with clear visualization of
the internalized NPs, and in addition, they showed a significant
increase in fluorescence intensity with incubation time with
strong fluorescence even after 8 days of treatment as compared
to the native DOX (Fig. 7d). These findings are in agreement
with the previous results obtained for quantitative measure-
ment. These quantitative and qualitative results of the cellular
uptake of the NPs provide strong evidence for the targeting
effect of folate decoration for Y-79 cells.
3.4 Drug-induced changes in mitochondrial transmembrane
potential
Mitochondrial changes, including variations in mitochon-
drial membrane potential (Δ=m), are the key events during
drug-mediated apoptosis (Zamzami et al. 1995). To delin-
eate this mechanism, the lipophilic cation JC-1 was chosen
as it is more specific for mitochondria than other fluores-
cent dyes such as DiOC6(3) or Rhodamine 123 (Ly et al.
2003; Salvioli et al. 1997), and this was used to determine
whether DOX induces alterations in the Δ=m. As compared
to untreated cells, DOX-treated cells exhibited a dramatic
decrease in the population of cells with J-aggregates
(93.6%) and subsequent increase in the monomeric form
(6.18%) indicating rapid depolarization of the mitochondri-
al membranes. The alterations in the Δ=m were much more
evident in the case of NP formulations, especially for the
folate-decorated NPs (70.2%, JC-1 aggregates and 29.7%,
JC-1 monomers) for the same concentration of drug
exposure (Fig. 8).
3.5 Kinetic analysis of drug-induced mitochondrial
translocation of cytochrome c
Mitochondria play an essential role in apoptosis triggered
by various chemical agents (Sareen et al. 2006). Cyto-
chrome c is normally localized in the space between the
outer and inner mitochondrial membrane and is only
released into the cytosol in the setting of apoptosis (Kluck
et al. 1997). The mitochondrial response includes the
release of cytochrome c into the cytosol where it binds to
Apaf-1, allowing the recruitment of caspase-9 and the
formation of an apoptosome complex, resulting in caspase-
3 activation and execution of cell death (Green and Reed
1998). To determine whether DOX initiates this cell death
mechanism, we tested whether it triggers the release of
cytochrome c from the mitochondria and the amount of
DOX-CNPs
G2/M =38.78 % 
Control
G2/M = 25.01% 
DOX
G2/M =29.84% 
G2/M =88.23 % 
DOX-CNPs-FA
Fig. 6 Cell cycle analysis by
flow cytometry. For 48 h, 1×
105 cells/ml were treated with
5 μM of native DOX and equiv-
alent concentrations of DOX in
NPs (DOX-CNP and DOX-
CNP-FA). Thereafter, to the
treated cells, 20 μg/ml of propi-
dium iodide solution was added
and incubated at room tempera-
ture in dark for 30 min before
flow cytometric analysis. Cell
cycle distribution was deter-
mined by analyzing 15,000
ungated cells using a FACScan
flow cytometer. Content of DNA
is represented on the x-axis;
number of cells counted is rep-
resented on the y-axis. Results
are representative of one of three
independent experiments
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Fig. 7 Cellular uptake as a function of particle surface modification a
folic acid conjugation increases nanoparticle endocytosis in Y-79 cells.
Y-79 cells were incubated with native DOX and nanoparticles at a
dose of 300 μg/ml for 2 h and the number of Y-79 cells with the
endocytosed CNPs was detected by flow cytometry. a Control. b
DOX. c DOX-CNPs. d DOX-CNPs-FA. Results are representative of
one of three independent experiments. b Bar graph depicts the data
from Fig. 7a demonstrating the uptake efficiency of various
formulations. Data as mean±S.D., n=3. **p<0.005, DOX in solution
versus DOX-CNPs and DOX-CNP-FA. c Competitive inhibition of
DOX-CNP-FA uptake by the addition of native FA. Y-79 cells were
cultured overnight with 0–3 mM of native folic acid after which the
cells were left untreated (control) or incubated with 300 μg/ml of
nanoparticles for 2 h. Mean fluorescence intensity (MFI) of DOX
fluorescence in the cells were measured and the value normalized to
particle endocytosis of Y-79 cells. Data represent mean±S.D., n=3. d
Time course study of intracellular retention of DOX-loaded NPs in Y-
79 cells. Cells were treated with 5 μM of native DOX and equivalent
concentrations of DOX in NPs (DOX-CNP and DOX-CNP-FA) in the
growth medium. Cells treated with DOX in solution showed a
decrease in green fluorescence intensity with incubation time, whereas
DOX-CNPs demonstrated an increase with FA-conjugated CNPs
demonstrating the fluorescence of the drug lasting up to 8 days.
Results are representative of one of three independent experiments
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cytochrome c released was examined in the cytosolic and
mitochondrial fractions by western blot analysis. DOX
induced slight release of cytochrome c into the cytosol as
early as 2 h after the treatment (Fig. 9a). In contrast, both
DOX-loaded NPs induced a greater amount of cytochrome
c release, the effect being more prominent in case of DOX-
CNPs-FA. This may be due to the substantial loss of =m,
and as a consequence, the mitochondrial membranes are
easily damaged leading to a massive leakage of cytochrome
c. It was further observed that the quantity of the protein
released increased with time and after 48 h, large quantities
of the protein accumulated in the cytosol. Furthermore, it
was observed that folate-decorated NPs were most effective
in causing the release of cytochrome c at all time intervals
(Fig. 9a). The temporal profile of cytosolic accumulation of
cytochrome c parallels its release from the mitochondria.
From these results, it was evident that DOX-induced
apoptotic death is mediated by mitochondria-dependent
signaling pathways in Y-79 cell line.
3.6 Participation of caspase-9 and caspase-3
in DOX-induced apoptosis
Loss of =m and cytochrome c release by numerous
apoptotic stimuli including chemotherapeutic drugs lead to
apoptosis which is executed by the linked activation of
initiator (e.g., caspase-9) and effector caspases (e.g.,
caspase-3; Earnshaw et al. 1999). Caspase activation was
assessed by western blotting after 48 h in accordance to the
peak cytochrome c release, utilizing antibodies that detect
both the procaspase as well as the cleaved caspase
fragments. Based on these criteria, Fig. 9b shows evidence
for DOX-induced activation of the initiator caspase (cas-
pase-9) and the effector caspase (caspase-3). It was evident
that all formulations caused activation of caspases, with the
effects being most prominent in case of DOX-CNPs-FA,
which caused greater cleavage of the procaspases into the
active caspases.
4 Discussion
Targeting is especially relevant in case of cancer therapies,
as most of the commonly used anticancer drugs have
serious side effects due to non-specific actions on healthy
cells. The folate receptor, which normally is expressed only
at the luminal surface of polarized epithelia, has been found
to be overexpressed on the surface of several cancer cells,
including retinoblastoma (Kansara et al. 2008; Leamon and
Low 2001; Leamon and Reddy 2004). Thus, due to this
distinguishing feature between normal and cancer cells,
folic acid has emerged as an attractive targeting ligand for
selective delivery, and thus is used for the surface
conjugation to NPs. In this paper, our goal was to prepare
highly monodisperse polymeric nanoparticles with high
doxorubicin loading and folate decorated on the NP surface
for site-specific targeting. These NPs, in addition, may be
specifically suitable for ocular drug delivery because of its
excellent mucoadhesive properties and its ability to enhance
the penetration of large molecules across mucosal surface
(Sahoo et al. 2008).
In our studies, doxorubicin-loaded chitosan NPs of
around 300 nm were synthesized and developed for the
treatment of retinoblastoma (Fig. 1). These NPs were then
surface conjugated with FA in order to achieve site-specific
targeting. Conjugation of FA to the NP surface was
confirmed by NMR and FTIR (Figs. 2 and 3a). A typical
biphasic release pattern of doxorubicin from the NPs was
obtained which may be due to the faster release of the
surface-adsorbed drug (burst effect) and slower release
thereafter, as the drug gradually diffuses from the NPs
(Fig. 3b). A sustained release of the drug from the NPs is
important as a continuous exposure of the tumor cells to
anticancer drugs of a relatively lower but safer concentra-
tion that gives little chance for the tumor blood vessels to
grow, resulting in much better efficacy and fewer side
effects than intermittent chemotherapy.
Once the NPs were synthesized and characterized, the
cytotoxic potential of the various formulations was deter-
mined as the efficacy of the formulations to defeat cancer
cells is reflected by their cytotoxicity. A quantitative
evaluation of in vitro therapeutic effect of a dosage form
is IC50, which is defined as the drug concentration needed

























Fig. 8 DOX disrupts normal mitochondrial membrane potential. Y-79
cells were treated with 5 μM of native DOX and equivalent
concentrations of DOX in NPs (DOX-CNP and DOX-CNP-FA) for
48 h and were then stained with JC-1 to access the mitochondrial
transmembrane potential by flow cytometry. Results are representative
of one of three independent experiments
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period. It can be calculated from the in vitro cellular
viability data that judging by IC50 after the treatment, the
IC50 is 15.11 μM for native DOX, 10.2 μM for DOX-CNP
formulation, and 3.06 μM for folate decorated DOX-CNP
formulation, which means that DOX-CNPs-FA is approx-
imately threefold more effective than the NP formulation
and approximately fivefold more effective than the native
DOX (Fig. 4). It is thus clear that folate-conjugated CNPs
demonstrated higher cytotoxicity than the NP formulation
and native doxorubicin, which means that for the same
therapeutic effect, the drug needed for the folate-conjugated
CNP formulation could be much less than the NP
formulation and native doxorubicin itself. Nanoparticles
may be more cytotoxic than the free drug as the polymeric
envelope protects the drug and prevents the drug from
being degraded by the harsh in vivo environment (Panyam
and Labhasetwar 2003; Torchilin 2005). In comparison, the
free drug in solution is vulnerable to all such conditions and
maybe degraded and as a result is not able to exert its
antiproliferative effects to the maximum. Moreover, the
nanoparticles form a drug depot wherein the drug is
released slowly as compared to the native drug, and thus,
a continuous exposure and sustained release of the drug
over a period of time is more effective. This may also be
the reason that both the formulations of CNPs showed
greater apoptosis and enhanced cell cycle arrest than the
native DOX at the same concentration, which further
corroborated the results of the cytotoxicity assay (Figs. 5
and 6). The development of the CNPs formulation of DOX,
thus, can enhance the therapeutic effect as well as prevent
the toxic effects of the drug applied at high concentrations.
Moreover, it was evident from the various cytotoxicity
assays that folate-conjugated CNPs is a better candidate for
drug delivery as it provides enhanced cytotoxicity which
may be due to greater cellular uptake by the folate
receptors. To validate this hypothesis, the cellular uptake
of the various formulations by Y-79 cells was determined in
vitro to demonstrate the penetration of the CNPs into the
cells and the targeting effects of the FA-decorated CNPs.
Furthermore, a competitive experiment using different
concentrations of FA together with DOX-CNPs-FA was
performed to verify that the uptake was mediated by the FA
receptor. The uptake experiments confirmed the manifold-
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Cytochrome c
       15 kDa 
Control        DOX DOX-NP DOX NP-FA 
Procaspase-9 (50 kDa) 
Cleaved Caspase-9 (37 
and 35 kDa) 
Procaspase-3 (35 kDa) 
Cleaved Caspase-3 (18 kDa) 
β-actin (43 kDa) 
(b) 
(a) 2 h 24 h 48 h 
Fig. 9 Western blot analysis to determine the apoptotic mechanism of
doxorubicin a DOX causes cytochrome c release from mitochondria.
Y-79 cells were treated with 5 μM of native DOX and equivalent
concentrations of DOX in NPs (DOX-CNP and DOX-CNP-FA) for 2,
24, and 48 h. Cytosolic and mitochondrial fractions from intact cells
were prepared and analyzed for cytochrome c levels by immunoblot-
ting using an anti-cytochrome c antibody. Samples obtained from the
time course of different fractions (cytosol or mitochondria) were
adjusted for equal protein loading by determination of concentrations
with the Bradford assay. β-actin was used as a standard for the equal
loading of protein in the lanes. b DOX activates caspase-9 and
caspase-3. Y-79 cultures were treated with 5 μM of native DOX and
equivalent concentrations of DOX in NPs (DOX-CNP and DOX-
CNP-FA) for 48 h. Thereafter, the cells were harvested and lysed at
the indicated times after treatment, and the protein extracts were
extracted and analyzed by western blot for the presence of activated
caspase-9 and caspase-3. β-actin was used as a standard for the equal
loading of protein in the lanes
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DOX-CNPs and the native DOX (Fig. 7a, b). Besides, the
inhibition of uptake of folate-decorated CNPs by free FA in
a dose-dependent manner demonstrates that the particle
uptake is mediated by the FA receptor (Fig. 7c). Thus, the
key for the success of the targeted formulation is due to FA
that conveys targeting properties to the carrier, which
involves the cell–folate receptor interaction, internalization,
and intracellular drug release. Though, we agree that even
at a folic acid concentration of 3 mM, some internalization
of the NPs occurs which may be due to the inherent ability
of CNPs to enter the cells by endocytosis. Confocal
microscopic studies also demonstrated greater intracellular
retention of the DOX-CNPs-FA as compared to the DOX-
CNPs and native DOX (Fig. 7d). Thus, the greater
antiproliferative effect of DOX-loaded CNPs-FA can be
very well correlated with the duration of its intracellular
retention. Our experimental conclusions that FA causes
ligand specific internalization and enhanced endocytosis of
NPs which leads to greater cytotoxicity can also be
supported by similar findings of various research groups.
Folate decorated poly (lactide)–vitamin E TPGS nano-
particles for the targeted delivery of paclitaxel was
synthesized by the group of Pan et al. in which they have
shown the enhanced advantages of the NP formulations
versus the native drug in achieving better therapeutic effect
(Pan and Feng, 2008). The advantage of folate targeting
was also exploited by the group of Rosenholm et al. in
which they synthesized folate-conjugated porous hybrid
silica nanoparticles for targeting to cancer cells. Signifi-
cantly enhanced uptake of the formulated NPs by the
cancer cells supports the enhanced endocytosis of the NPs
by folate receptor expressing cells (Rosenholm et al. 2009).
In another study by Liu et al., in which folic acid-
conjugated nanoparticles of mixed lipid monolayer shell
and biodegradable polymer core for targeted delivery of
docetaxel was synthesized, they showed that folic acid-
conjugated NPs facilitate the targeted delivery of docetaxel
as well as enhanced cytotoxicity (Liu et al. 2009).
Doxorubicin is one of those cytotoxic drugs that are
known to mediate apoptosis through the intrinsic mito-
chondrial pathway in many cancer cell lines (Guo et al.
2000; Kluza et al. 2004; Liu et al. 2010). In our studies
this pathway was investigated as these studies might
provide the molecular evidence of enhancement of
apoptosis by the nanoparticles. As already discussed, the
mitochondrial-dependent apoptotic pathway is initiated
through the disruption of the mitochondrial membrane
potential. This disruption leads to the release of cyto-
chrome c and the formation of the apoptosome complex
(cytochrome c/Apaf-1/caspase-9) and activation of the
caspase cascade. The changes in mitochondrial membrane
potential were analyzed by the JC-1 dye that can be used
to predict the polarization state of the mitochondria. It was
evident that due to the targeting effects, Y-79 cells were
more sensitive to FA-conjugated NPs than the DOX-CNPs
and the native DOX (Fig. 8). Due to the collapse of =m as
a result of the leakiness of the inner mitochondrial
membrane, cytochrome c is released into the cytosol,
which appears to precede the activation of caspase-9 and
caspase-3. The temporal release profile of cytochrome c
suggests that greater quantity of the protein accumulated
in the cytosol after treatment with DOX-CNPs-FA
(Fig. 9a). This was also followed by enhanced activation
of both the caspases, which suggests its advantage over
DOX-CNPs and native DOX (Fig. 9b).
The mechanism of apoptosis by doxorubicin in retino-
blastoma has not been studied till date. Taken together, our
results point to a general mechanism of apoptosis induction
by DOX in Y-79 cells that involves a progressive loss of
mitochondrial membrane potential and activation of the
intrinsic mitochondrial/caspase-9 specific pathway, con-
firming previous findings from other groups in vivo as
well as in different cancer cell lines (Childs et al. 2002; Gao
et al. 2001; Kluza et al. 2004; Liu et al. 2010). In all cases,
FA-decorated NPs showed superior efficacy as a drug
delivery system as compared to DOX-CNPs and native
DOX, which suggests that targeting of Y-79 with folic acid
may play a pivotal role in increasing the therapeutic
efficacy of drugs as well as decreasing the deleterious side
effects by considerable reducing the dosage. Though, these
carriers do hold promise as a drug delivery system for the
ocular tissues, further studies are warranted to determine the
in vivo efficacy of these folate-decorated DOX-CNPs for
the treatment of retinoblastoma.
5 Conclusion
In this study, FA-conjugated and DOX-loaded CNPs are
prepared and characterized for targeting the cancer cells
rich in folate receptors on their surface. DOX-loaded CNPs
with surface-conjugated FA, demonstrated a superior
cellular uptake over non-targeted NPs due to FA receptor-
mediated endocytosis, which also resulted in an increased
cytotoxicity. FA-targeted CNPs also showed enhanced
apoptosis and cleavage of downstream procaspases into
active caspases for the augmentation of apoptosis. Thus,
this work established the better efficacy of DOX-CNP-FA
due to the targeting ligand (FA), and this work may pave
the way for targeted therapy for the treatment of retino-
blastoma via a safe drug delivery vehicle and with minimal
undesirable effects. However, it should be pointed out that
this is only a proof-of-concept investigation for design of
FA-conjugated and drug-loaded CNPs. Further in vivo
investigation should be carried out to determine the
therapeutic efficacy of these CNPs.
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